Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2/3 1Phase 2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Conditions

Breast Neoplasms 1256Neoplasms 1074Carcinoma, Non-Small-Cell Lung 874Prostatic Neoplasms 714Lung Neoplasms 596Colorectal Neoplasms 590Neoplasm Metastasis 452Multiple Myeloma 432Leukemia, Myeloid, Acute 423Pancreatic Neoplasms 370Ovarian Neoplasms 367Melanoma 324Carcinoma, Hepatocellular 299Squamous Cell Carcinoma of Head and Neck 276Brain Neoplasms 275Recurrence 273Stomach Neoplasms 245Head and Neck Neoplasms 241Glioblastoma 239Carcinoma, Renal Cell 227Lymphoma 226Triple Negative Breast Neoplasms 225Precursor Cell Lymphoblastic Leukemia-Lymphoma 222Hematologic Neoplasms 212Urinary Bladder Neoplasms 211Uterine Cervical Neoplasms 200Endometrial Neoplasms 199Sarcoma 195Glioma 194Lymphoma, Non-Hodgkin 188

Interventions

Alpelisib 2mirdametinib 1Injections, Intralesional 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphatic Abnormalities × 90 days × Clear all
NCT05948943 2026-05-12

EPIK-L1

Novartis

Phase 2/3 Recruiting
232 enrolled

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

NCT05983159 2026-05-05

TARGET-VM

Murdoch Childrens Research Institute

Phase 2 Recruiting
50 enrolled

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

NCT07189832 2026-04-28

Bleomycin Intralesional Injections of Cystic Hygromas

Delta University for Science and Technology

Phase NA Completed
30 enrolled

Lymphangioma, Cystic, Lymphatic Abnormalities

NCT06239480 2026-03-27

SELVA

Palvella Therapeutics, Inc.

Phase 3 Active not recruiting
51 enrolled

Congenital Abnormalities, Lymphangioma, Lymphatic Abnormalities, Vascular Malformations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡